copper (64Cu) chloride - søkeresultat

viatris healthcare limited - imikimod - condylomata acuminata; keratosis; keratosis, actinic; carcinoma, basal cell - antibiotici i kemoterapeutici za dermatološku uporabu - imiquimod cream is indicated for the topical treatment of :external genital and perianal warts (condylomata acuminata) in adults. small superficial basal cell carcinomas (sbccs) in adults. clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (aks) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.

Den europeiske union - kroatisk - EMA (European Medicines Agency)

arzerra

novartis europharm ltd - ofatumumab - leukemija, limfocitna, kronična, b-stanica - monoklonska protutijela - ranije леченным kroničnim лимфолейкозом (ХЛЛ): vlasnika u kombinaciji s хлорамбуцилом ili бендамустин indiciran za liječenje bolesnika s ХЛЛ, koji nije dobio pre tretmana i koji nemaju pravo na флударабин-terapija. ponavljanje ХЛЛ: vlasnik je navedeno u kombinaciji s флударабином i циклофосфаном za liječenje odraslih pacijenata s relaps ХЛЛ. Рефрактерным ХЛЛ: vlasnik je indiciran za liječenje ХЛЛ kod pacijenata koji резистентны na флударабина i алемтузумаб.

Den europeiske union - kroatisk - EMA (European Medicines Agency)

axura

merz pharmaceuticals gmbh - memantin hidroklorid - alzheimerova bolest - ostali lijekovi protiv demencije - liječenje bolesnika s umjerenom ili teškom alzheimerovom bolesti.

Den europeiske union - kroatisk - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - prekursorska stanica limfoblastične leukemije-limfom - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.